CN1303987C - 注射用盐酸艾司洛尔冻干粉针剂及其制备方法 - Google Patents
注射用盐酸艾司洛尔冻干粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN1303987C CN1303987C CNB2004100657861A CN200410065786A CN1303987C CN 1303987 C CN1303987 C CN 1303987C CN B2004100657861 A CNB2004100657861 A CN B2004100657861A CN 200410065786 A CN200410065786 A CN 200410065786A CN 1303987 C CN1303987 C CN 1303987C
- Authority
- CN
- China
- Prior art keywords
- injection
- water
- esmolol hydrochloride
- esmolol
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000843 powder Substances 0.000 title claims abstract description 90
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960001015 esmolol hydrochloride Drugs 0.000 title claims abstract description 69
- 239000007924 injection Substances 0.000 title claims abstract description 62
- 238000002347 injection Methods 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 69
- 239000000243 solution Substances 0.000 claims abstract description 59
- 239000008215 water for injection Substances 0.000 claims abstract description 53
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 238000001914 filtration Methods 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 238000004108 freeze drying Methods 0.000 claims abstract description 17
- 238000012856 packing Methods 0.000 claims abstract description 17
- 239000013543 active substance Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 54
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 44
- 238000001035 drying Methods 0.000 claims description 35
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 20
- 229930195725 Mannitol Natural products 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 239000000594 mannitol Substances 0.000 claims description 20
- 235000010355 mannitol Nutrition 0.000 claims description 20
- 238000000859 sublimation Methods 0.000 claims description 18
- 230000008022 sublimation Effects 0.000 claims description 18
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 16
- 239000012982 microporous membrane Substances 0.000 claims description 16
- 229920002307 Dextran Polymers 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000011343 solid material Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 15
- 238000003860 storage Methods 0.000 abstract description 2
- 239000011148 porous material Substances 0.000 abstract 1
- 238000005096 rolling process Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 42
- 229960003745 esmolol Drugs 0.000 description 37
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 37
- 238000005352 clarification Methods 0.000 description 34
- 238000004519 manufacturing process Methods 0.000 description 29
- 238000012360 testing method Methods 0.000 description 27
- 239000003814 drug Substances 0.000 description 21
- 238000005516 engineering process Methods 0.000 description 19
- 238000009472 formulation Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 238000007689 inspection Methods 0.000 description 15
- 230000005496 eutectics Effects 0.000 description 14
- 230000008014 freezing Effects 0.000 description 14
- 238000007710 freezing Methods 0.000 description 14
- 239000008141 laxative Substances 0.000 description 14
- 238000011068 loading method Methods 0.000 description 14
- 230000001543 purgative effect Effects 0.000 description 14
- 238000005057 refrigeration Methods 0.000 description 14
- 230000002040 relaxant effect Effects 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 210000001992 atrioventricular node Anatomy 0.000 description 2
- 238000012550 audit Methods 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940110331 bextra Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Abstract
Description
批号 | 外观 | 澄明度 | pH值 | 水分(%) | 标示量(%) | 有关物质(HPLC,%) |
030503080311 | 白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末 | 符合规定符合规定符合规定 | 5.125.085.17 | 1.781.241.09 | 100.199.2699.37 | 0.360.380.36 |
条件 | 时间(天) | 性状 | 溶液颜色和澄清度 | 酸度(pH) | 标示量(%) | 有关物质(HPLC)% |
光照 | 0510 | 白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末 | 澄清无色澄清无色澄清无色 | 5.035.145.09 | 99.5598.6799.44 | 0.330.370.31 |
40℃ | 510 | 白色疏松块状物及粉末白色疏松块状物及粉末 | 澄清无色澄清无色 | 5.125.07 | 99.5198.85 | 0.340.32 |
60℃ | 510 | 白色疏松块状物及粉末白色疏松块状物及粉末 | 澄清无色澄清无色 | 5.115.14 | 99.0799.78 | 0.350.27 |
批号 | 时间(月) | 性状 | 溶液颜色与澄清度 | 酸度(pH) | 标示量(%) | 有关物质(HPLC,%) |
20030222 | 01236 | 白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末 | 无色澄清无色澄清无色澄清无色澄清无色澄清 | 5.035.135.094.975.11 | 99.5599.1198.9798.9599.55 | 0.330.360.380.280.37 |
20030225 | 01236 | 白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末 | 无色澄清无色澄清无色澄清无色澄清无色澄清 | 5.175.255.215.145.20 | 99.2599.81100.099.0099.50 | 0.280.340.350.290.34 |
20030228 | 01236 | 白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末 | 无色澄清无色澄清无色澄清无色澄清无色澄清 | 5.115.145.095.205.21 | 100.399.4099.3398.6599.87 | 0.320.340.340.280.36 |
批号 | 时间(月) | 性状 | 溶液颜色与澄清度 | 酸度(pH) | 标示量(%) | 有关物质(%) | 无菌 |
20030222 | 0369 | 白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末 | 无色澄清无色澄清无色澄清无色澄清 | 5.035.095.124.99 | 99.5598.8699.3998.94 | 0.330.290.360.32 | 符合规定符合规定符合规定符合规定 |
20020225 | 0369 | 白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末 | 无色澄清无色澄清无色澄清无色澄清 | 5.175.215.245.19 | 99.2599.8899.2599.44 | 0.280.260.360.35 | 符合规定符合规定符合规定符合规定 |
20020228 | 0369 | 白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末白色疏松块状物及粉末 | 无色澄清无色澄清无色澄清无色澄清 | 5.115.185.075.16 | 100.399.7798.7898.90 | 0.320.280.330.36 | 符合规定符合规定符合规定符合规定 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100657861A CN1303987C (zh) | 2004-11-19 | 2004-11-19 | 注射用盐酸艾司洛尔冻干粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100657861A CN1303987C (zh) | 2004-11-19 | 2004-11-19 | 注射用盐酸艾司洛尔冻干粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634002A CN1634002A (zh) | 2005-07-06 |
CN1303987C true CN1303987C (zh) | 2007-03-14 |
Family
ID=34846547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100657861A Expired - Fee Related CN1303987C (zh) | 2004-11-19 | 2004-11-19 | 注射用盐酸艾司洛尔冻干粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1303987C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102232930B (zh) * | 2010-05-06 | 2013-03-27 | 南京海辰药业有限公司 | 盐酸兰地洛尔药物组合物及其制备方法 |
AU2015364280A1 (en) | 2014-12-18 | 2017-07-06 | Windgap Medical, Inc. | Method and compositions for dissolving or solubilizing therapeutic agents |
CN111848420A (zh) * | 2020-07-22 | 2020-10-30 | 杭州煌森生物科技有限公司 | 一种盐酸艾司洛尔的新晶型及制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
CN1455669A (zh) * | 2001-01-12 | 2003-11-12 | 巴克斯特国际公司 | 艾司洛尔制剂 |
CN1481786A (zh) * | 2003-07-29 | 2004-03-17 | 吉林市卓怡康纳制药有限公司 | 注射用盐酸索他洛尔及其制备方法 |
-
2004
- 2004-11-19 CN CNB2004100657861A patent/CN1303987C/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
US6528540B2 (en) * | 2001-01-12 | 2003-03-04 | Baxter International Inc. | Esmolol formulation |
CN1455669A (zh) * | 2001-01-12 | 2003-11-12 | 巴克斯特国际公司 | 艾司洛尔制剂 |
CN1481786A (zh) * | 2003-07-29 | 2004-03-17 | 吉林市卓怡康纳制药有限公司 | 注射用盐酸索他洛尔及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1634002A (zh) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1093901A (zh) | 烟霉醇衍生物的稳定药物组合物 | |
CN1792362A (zh) | 阿比朵尔及其盐的静脉给药制剂及制备方法 | |
CN1864684A (zh) | 多索茶碱冻干粉针注射剂及其制备方法 | |
CN1149987C (zh) | 含索他洛尔右旋和左旋异构体混合物的药物组合物 | |
CN1219132A (zh) | 前列腺素i衍生物缓释制剂 | |
CN1303987C (zh) | 注射用盐酸艾司洛尔冻干粉针剂及其制备方法 | |
CN1827109A (zh) | 一种以兰洛地尔及其盐为活性成分的冻干粉针制剂及其制备工艺 | |
CN1820748A (zh) | 一种左旋奥硝唑冻干粉针注射剂 | |
CN1948297A (zh) | 烷醇哌嗪衍生物光学异构体或其盐及其应用 | |
CN1843356A (zh) | 注射用多拉司琼及其药物上可接受的盐的粉针制剂及其制备方法 | |
CN1555795A (zh) | 注射用盐酸昂丹司琼冻干粉针剂及制备方法 | |
CN1732913A (zh) | 一种稳定性好的棓丙酯注射液及其制备方法 | |
CN100341495C (zh) | 格列本脲固体分散体、口服组合物及其制备方法 | |
CN1907420A (zh) | 一种治疗心肌缺血性疾病的药物及其制备方法 | |
CN1555805A (zh) | 注射用磷苯妥英钠冻干粉针剂及制备方法 | |
CN1628679A (zh) | 齐墩果酸-3-O-β-D-吡喃葡萄糖醛酸苷在制备治疗心律失常药物中的应用 | |
CN1660092A (zh) | 注射用兰索拉唑钠制剂及其制备方法 | |
CN1903180A (zh) | 注射用呋塞米冻干制剂及制备方法 | |
CN1824172A (zh) | 供静脉注射用天麻素冻干粉针剂及其制备工艺 | |
CN1449784A (zh) | 复方莪术油制剂及其制备方法 | |
CN1565438A (zh) | 5-羟甲基糠醛类用于制备神经系统用药的用途 | |
CN1561976A (zh) | 复合溶媒的稀释后供静脉注射的大蒜素浓缩溶液 | |
CN1720905A (zh) | β-细辛醚在制药中的应用 | |
CN1283245C (zh) | 硝酸异山梨酯的冻干粉针及其制备方法 | |
CN1568943A (zh) | 硝酸甘油软膏及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: JIANGSU AOSAIKANG PHARMACEUTICAL Co.,Ltd. Assignor: Chen Qingcai|Zhao Jun Contract fulfillment period: 2007.4.8 to 2024.11.18 Contract record no.: 2008320000673 Denomination of invention: Esmolol Hydrochloride freeze dried powder for injection and its preparation method Granted publication date: 20070314 License type: Exclusive license Record date: 20081009 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.4.8 TO 2024.11.18; CHANGE OF CONTRACT Name of requester: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. Effective date: 20081009 |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ZHAO JUN Owner name: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHEN QINGCAI Effective date: 20110413 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210029 NANJING AOKANG MEDICAL TECHNOLOGY CO., LTD., TOWER C, 20/F, HANZHONG NEW CITY, NO. 1, HANZHONGMEN STREET, NANJING CITY, JIANGSU PROVINCE TO: 211112 NO. 699, KEJIAN ROAD, JIANGNING SCIENCE PARK, NANJING CITY, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110413 Address after: 211112 Jiangsu Province, Nanjing City, Jiangning Science Park Road No. 699 Patentee after: JIANGSU AOSAIKANG PHARMACEUTICAL Co.,Ltd. Address before: 210029, Jiangsu City, Hanzhoung province Nanjing Avenue 1, Hanzhoung metro, 20 floor, block C, Nanjing AOKANG Pharmaceutical Technology Co., Ltd. Co-patentee before: Zhao Jun Patentee before: Chen Qingcai |
|
C56 | Change in the name or address of the patentee |
Owner name: JIANGSU AOSAIKANG PARHMACEUTICAL CO., LTD. Free format text: FORMER NAME: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 211112 Jiangsu Province, Nanjing City, Jiangning Science Park Road No. 699 Patentee after: JIANGSU AOSAIKANG PHARMACEUTICAL Co.,Ltd. Address before: 211112 Jiangsu Province, Nanjing City, Jiangning Science Park Road No. 699 Patentee before: JIANGSU AOSAIKANG PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 211112 Kejian Road, Jiangning Science Park, Nanjing City, Jiangsu Province, 699 Patentee after: JIANGSU AOSAIKANG PHARMACEUTICAL Co.,Ltd. Address before: 211112 Kejian Road, Jiangning Science Park, Nanjing City, Jiangsu Province, 699 Patentee before: JIANGSU AOSAIKANG PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070314 Termination date: 20211119 |
|
CF01 | Termination of patent right due to non-payment of annual fee |